Valproic Acid is a carboxylic or inorganic acid with defined pKₐ value governing its ionisation state across the pH range of biological fluids and pharmaceutical formulations. In pharmaceutical development, Valproic Acid serves roles including counter-ion selection for API salt formation, pH adjustment and buffering in liquid formulations, and chemical reagent in API synthesis. Toxicological assessment for PDE derivation evaluates local irritancy effects on gastrointestinal mucosa, skin, and respiratory epithelium alongside systemic metabolic consequences of absorbed quantities, with the most sensitive endpoint in the most relevant study forming the POD.
The intraspecies uncertainty factor F2 for Valproic Acid covers the range of pharmacokinetic and pharmacodynamic variability within the human population, ensuring the derived PDE is protective for sensitive subgroups including paediatric patients with immature CYP450 activity, elderly patients with reduced hepatic and renal clearance, patients with
